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ABSTRACT The generation of lymphoid cells in mice
depends on the function of the Ikaros protein. Ikaros has been
characterized as a lymphoid-restricted, zinc-finger transcrip-
tion factor that is derived from an alternatively spliced
message. Ikaros knockout mice have defects in multiple cell
lineages, raising the question of whether the protein regulates
multiple committed progenitors andyor multipotent stem
cells. To address this issue, we examined Ikaros expression in
purified populations of multipotent cells and more committed
progenitors. We found that the DNA-binding isoforms of
Ikaros were localized in the nucleus of the most primitive
hematopoietic stem cell subset. Changes in the RNA splicing
pattern of Ikaros occurred at two stages: (i) as long-term
self-renewing stem cells differentiated into short-term self-
renewing stem cells and (ii) as non-self-renewing multipotent
progenitors differentiated into lymphoid-committed progen-
itors. Unexpectedly, we found Ikaros localized to heterochro-
matin in Abelson-transformed pre-B lymphocytes by using
immunogold electron microscopy. These observations suggest
a complex role for Ikaros in lymphoid development.
The hematopoietic system in mammals is continuously regen-
erated by a rare population of self-renewing, multipotent stem
cells resident within the adult bone marrow (1, 2). Hemato-
poietic stem cells (HSC) can be divided into long-term self-
renewing (LT-HSC) and short-term self-renewing (ST-HSC)
subsets based on the differential expression of Mac-1 surface
antigen. A third, non-self-renewing population of multipotent
progenitor cells (MPP), which expresses low levels of CD4
surface marker, can also be purified (3). These three subpopu-
lations form a lineage from the most primitive long-term HSC
to the most mature multipotent progenitor prior to, or in the
process of, lymphoid commitment (4).
Refined definitions of cellular intermediates in the differ-
entiation of HSC into progenitor B and T lymphocytes provide
a framework for understanding the roles different genes play
in regulating developmental transitions (4–7). Insights into the
genetic programs that regulate these developmental fate de-
cisions have come from gene knockout experiments in the
mouse (8–10). One mutation that has a profound effect on the
development of the lymphoid system, including B, T, NK, and
dendritic cells, is that seen in Ikaros knockout mice (11, 12).
Ikaros was first characterized as a lymphoid-restricted,
zinc-finger transcription factor that bound an important reg-
ulatory element within the CD3d enhancer (13). The same
factor (referred to as LyF-1) was also identified as an activity
in nuclear extracts that bound a functionally important site
within the terminal deoxynucleotide transferase promoter
(14). Subsequent experiments by two groups defined at least
eight splice variants of the gene in different lymphoid cell lines
(15, 16). All of the variants have common N-terminal and
C-terminal domains, the latter of which contains two zinc
fingers that mediate interactions between the different Ikaros
isoforms (17) and at least two other related proteins (ref. 18;
K. Hahm and S. Smale, unpublished results). Splice variants
that do not include at least three of the four internal zinc
fingers do not bind single Ikaros binding sites and functionally
interfere with the activity of the longer isoforms (17).
Mice homozygous for an Ikaros null allele, created by
deletion of the common C-terminal zinc fingers, have no B or
NK cells and severely reduced numbers of gd T cells and
thymic dendritic cells (12). ab T cells develop abnormally, with
skewing of mature T cells toward the CD4 lineage. In addition
to the lymphoid defects, there was also a striking defect in the
maturation of neutrophils, with an approximate 10-fold re-
duction in bone marrow Gr-11Mac-11 cells. Given the im-
pairments in lymphoid and myeloid differentiation, Ikaros may
regulate important sets of genes for both of these pathways in
hematopoietic stem cells. Alternatively, Ikaros may be re-
quired at independent stages in the development of both
neutrophils and lymphoid cells. To address this issue, we have
looked for expression of Ikaros RNA and protein in popula-
tions of multipotent and lymphoid-committed progenitor cells
purified by fluorescence-activated cell sorting (FACS).
MATERIALS AND METHODS
HSC Isolation and Sorting. Bone marrow cells were isolated
from 4- to 8-week-old C57BLyKa-Thy-1.1 mice, which were
bred and maintained at Stanford University Medical Center.
HSC were isolated as described (4). The LT-HSC phenotype
was sorted as Thy-1loSca-11Lineage2Mac-12CD42c-kit1. ST-
HSC were sorted as Thy-1loSca-11Lineage2Mac-1loCD42.
The MPP population was sorted as Thy-1loSca-11Mac-
1loCD4lo.
Pro-B, Pro-T, and Neutrophil Isolation. Progenitor B cells
were isolated from the bone marrow by sorting Thy-1.1loB2201
CD431IgM2 cells. Progenitor T cells were isolated from the
thymus as Thy-1.11(CD3, CD4, CD8)-/loc-kit1HSAhi. Myeloid
cells, including neutrophils, were isolated from the bone
marrow by sorting Gr-11Mac-11 cells.
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Reverse Transcriptase (RT)-PCR of Ikaros Isoforms. Cells
were sorted once and then clone-sorted directly into 0.2-ml
tubes containing 20 ml of RT lysis buffer [5 3 first strand buffer
(GIBCOyBRL)y10 mM DTTy2% Triton X-100y0.01% BSAy
0.2 mM spermidiney0.4 units RNasin (Promega)y100 ng of RT
primery0.5 mM each dNTP] to which 1 ml of Moloney murine
leukemia virus reverse transcriptase was added. Ten percent of
the cDNA reaction was amplified for 30 cycles by using the
outside primers listed below. Five percent of the first PCR
reaction was used for a second round of 30 cycles by using the
inside primers. Southern analysis was done with an oligonu-
cleotide (Ik-probe) complementary to the common N-
terminal exon.
Ikaros Oligonucleotides for RT-PCR and Southern Analy-
sis. The following oligonucleotides are written in 59-to-39
orientation: RT primer, GGGGGGCTTGTGCAGCTGGTA;
outside primers, TGGATGTCGATGAGGGTCAAG (59-
end) and GGGACTCAGCCCCCAGGTAGT (39-end); inside
primers, ACTCCAGATGAAGGGGATGAG (59-end) and
GGCATGTCTGACAGGCACTTG (39-end); Ik probe, TC-
CAAGAGTGATCGAGGCATG.
Immunohistochemistry. Sorted cell populations were fixed
in 220°C acetone for 5 min, dried, and blocked with 5% nonfat
dry milk. Cells were incubated with an anti-Ikaros antibody or
preimmune sera, washed, and then stained with a goat anti-
rabbitFITC antibody for an additional hour at 25°C. For neu-
trophils, a 50% glycerol in PBS solution containing 0.15 mgyml
Hoeschst 33342 was used.
Immunogold Electron Microscopy. Samples of the Abelson-
transformed pre-B cell lines, bcl2–3 and 2M3, were fixed in a
2% paraformaldehydey2.5% glutaraldehyde solution buffered
with 0.1 M sodium cacodylate (pH 7.4) for 10 min, dehydrated,
embedded in LX resin, and then cured at 50°C. Ultrathin
sections (approximately 70 nm) were picked up on nickel grids
and then processed for staining with the primary antibody
(preimmune serum, anti-Elf-1, N-and C-terminal-specific
Ikaros) for 2 h. Sections were washed, incubated with goat
anti-rabbit antibody conjugated to 10-nm gold particles for 2 h,
and then fixed by using 2% glutaraldehyde in PBS for 10 min.
Dried sections were counterstained by using uranyl acetate and
lead citrate.
RESULTS
Ikaros Is Nuclearly Localized in Long-Term Self-Renewing
HSC. To investigate the expression of Ikaros within the
multipotent progenitor subsets, we used an affinity-purified
polyclonal antibody raised against the C-terminal domain of
Ikaros (15). This antibody specifically stains all Ikaros isoforms
from a number of cell lines by Western blot and does not
cross-react with other Ikaros homologs that have been iden-
tified (ref. 15 and unpublished observations). Each population
was sorted twice consecutively to ensure that .98% of the
sorted cells would be of the defined phenotype.
Fixed LT-HSC stained brightly with the anti-Ikaros antibody
and showed a punctate pattern that was localized exclusively in
the nucleus of the cells (Fig. 1). In addition to the punctate
pattern, there was a general, more diffuse staining pattern
throughout the nucleus. Cells stained with preimmune serum
had undetectable levels of FITC stain. The punctate staining
pattern was also observed in the ST-HSC and MPP popula-
tions (data not shown). The observation that all LT-HSC
stained positively, of which approximately 4% are in S-G2-M
phase of the cell cycle, suggests that Ikaros is expressed and
nuclearly localized in both resting and cycling LT-HSC (3).
Ikaros Transcripts Present in Multipotent Progenitor Sub-
sets and Progenitor B and T Lymphocytes. We next wanted to
test which splice variants were present in multipotent and
lymphoid-committed progenitors and whether splicing pat-
terns change during lymphocyte differentiation. Cells of de-
fined phenotypes were sorted once and then resorted directly
into tubes for RT-PCR. Only five or ten cells of each popu-
lation were sorted in each tube to make it very unlikely that a
contaminating cell would affect the data. After two rounds of
PCR with nested primers, products were resolved on a gel and
then blotted for Southern analysis by using an internal oligo-
nucleotide probe complementary to a portion of the common
N-terminal exon. In the LT-HSC subset, only those isoforms
(Ik-1 and Ik-2; isoform VI and isoform V in the nomenclature
of ref. 15) that bind DNA were present with rare exceptions
(Fig. 2). In 24 independent, five-cell reactions of the LT-HSC
phenotype, Ik-6 was never detected, and Ik-4A was seen once.
FIG. 1. Ikaros expression in long-term self-renewing hematopoi-
etic stem cells. (A) LT-HSC purified from adult bone marrow with the
cell surface phenotype Sca-11Lin2Thy-1.1loc-kit1 were sorted twice
consecutively and then fixed on glass slides. Cells were stained with an
affinity-purified, rabbit polyclonal antibody to the C-terminal portion
of Ikaros. The secondary staining was done by using an FITC-
conjugated, goat anti-rabbit antibody. Red staining (a) represents the
Texas Red-conjugated, anti-Sca-1 antibody used in the sort. The
punctate staining pattern (b) was seen in all stem cell and lymphoid cell
populations analyzed with either the C-terminal antibody or with an
affinity-purified antibody to the N-terminal portion of Ikaros. (B)
LT-HSC were stained with rabbit preimmune serum followed by
secondary staining with goat anti-rabbitFITC antibody.
FIG. 2. Ikaros RNA splicing isoforms in stem cells and progenitor
B and T cell populations. HSC and pro-B cells from adult bone marrow
and pro-T cells from adult thymus were double-sorted based on cell
surface marker expression (See Materials and Methods). Five or ten
cells were cloned by FACS into tubes for RT-PCR. The RT reaction
was done by using an Ikaros-specific primer complementary to a
portion of exon 7. Two sequential rounds of nested PCR were
performed with an aliquot of cDNA using primers localized to exons
1y2 and exon 7. The Southern blot was probed with an internal
oligonucleotide complementary to sequence found in exon 1y2. The
vertical rectangles on the isoform diagram denote the zinc finger
domains within Ikaros.
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In eight independent reactions using ten cells, Ik-2AyIk-4 was
seen twice. Ik-2 was the predominant transcript in every
sample, although biases in the PCR reactions may skew the
representation of the individual messages. The amplified prod-
ucts were sequenced to ascertain the exon organization of each
transcript. We were unsuccessful in our effort to sequence the
band that migrated between Ik-1 and Ik-2. This band probably
represents a PCR artifact that has been seen by others (16).
As LT-HSC differentiate into multipotential cells with
short-term self-renewal capacity (ST-HSC), two new isoforms
were induced (Ik-2AyIk-4 and Ik-4A; Fig. 2). These messages
represent alternative usage of exons 5 and 6, which are present
in the largest Ikaros isoforms. Because isoforms Ik-2A and Ik-4
comigrate, they are described as Ik-2AyIk-4 in samples that
were not sequenced. Ik-2A was seen in sequencing reactions of
bands from the MPP population but did not appear in lym-
phocyte sequencing reactions. Ik-4 was seen in lymphocyte
sequencing reactions. Ikaros isoform expression in the non-
self-renewing MPP population did not differ from that seen in
ST-HSC (Fig. 2).
Differentiation of multipotent cells into a rare class of
IL-7R1Lin2Sca-1loc-kitloThy-1.12 clonogenic bone marrow
lymphoid progenitors, which only give rise to B, T, and NK
cells (19), gave a similar distribution of isoforms as that seen
in the ST-HSC and MPP populations, with the exception that
Ik-6 appeared in one out of eight samples at the five-cell level
(unpublished observation). In pro-B and pro-T cells, the
shortest of the isoforms, Ik-6, was again found (Fig. 2). This
isoform lacks the internal zinc finger exons that encode the
DNA binding domain of Ikaros. Interestingly, this isoform was
not seen in all of the samples and therefore may be present in
only a subset of pro-B and pro-T cells. These subsets might
include cells that are actively cycling or cells that are under-
going developmental transitions within given populations de-
fined by surface marker expression.
Ikaros knockout mice have defects in fetal liver B cells and
gd T cells (11, 12), suggesting that Ikaros is expressed in fetal
liver progenitor cells. We double-sorted the long-term self-
renewing, fetal liver HSC from 14 dpc fetal liver (20) and
analyzed Ikaros expression by RT-PCR. The Ikaros isoforms
present in fetal liver LT-HSC were similar to those expressed
in bone marrow ST-HSC and MPP populations (Ik-1 in 4y11
reactions, Ik-2 in 8y11, Ik-2AyIk-4 in 4y11, and Ik-4A in 2y11).
The similarities in Ikaros isoform expression between fetal
liver LT-HSC and adult ST-HSC suggests that the induced
Ikaros isoforms may not be involved in the decision of HSCs
to self-renew for short versus long intervals. The differences
presumably reflect other activities of these cells.
Ikaros Is Expressed and Nuclearly Localized in Mature
Neutrophils. Cells in the bone marrow and peripheral blood
that express high levels of Gr-1 and Mac-1 on their surface
represent an essentially pure population of mature neutrophils
(21). Neutrophils were purified by FACS, fixed on glass slides,
and stained with the anti-C-terminal Ikaros antibody. Prior to
staining, cells were incubated with an anti-FcR antibody
(2.4G2) to block binding of antibody to Fc receptor on the
surface of neutrophils. In three independent experiments, all
cells stained positively in the nucleus for Ikaros expression
(Fig. 3A). Cells stained with preimmune serum had no detect-
able staining (Fig. 3B). Neutrophils stained with an indepen-
dent antibody raised to the common N-terminal portion of
Ikaros gave similar results (unpublished observations).
Similar sorts were done to assess the Ikaros transcripts
present in neutrophils and in myeloid cells with lower levels of
Gr-1 and Mac-1 staining from both peripheral blood and bone
marrow. The latter population of cells in bone marrow largely
represent immature cells of the granulocytic and monocytic
cell lineages. In peripheral blood, Mac-1hiGr-1lo cells princi-
pally contain monocytes (ref. 21; Fig. 4). When cells were
assayed by RT-PCR, there was a reproducible amplification of
single isoforms in samples of five or ten cells in almost every
case (Fig. 4). This is in contrast to the multiple Ikaros isoforms,
which were detected in stem cells or lymphocytes (Fig. 2 and
Table 1). The predominant transcript, especially in peripheral
blood myeloid cells, was isoform 6. Interestingly, only about
50% of the samples yielded any amplification products. This
could be due to a lower level of Ikaros transcripts in myeloid
cells, higher ribonuclease activity in the cells, or the presence
of reverse transcriptase inhibitors, which make the reaction
FIG. 3. Ikaros expression in neutrophil populations from bone
marrow and peripheral blood. Pure populations of neutrophils were
double-sorted by using antibodies to myeloid lineage determinants.
Gr-1hiMac-1hi cells from peripheral blood (PB) and bone marrow
(BM) were fixed and stained with (A) the C-terminal, anti-Ikaros
antibody (FITC stain) or (B) preimmune serum. Bone marrow neu-
trophils were photographed using an FITC filter so the red staining
from the Gr-1PE (phycoerythrin) antibody used in the sort is not visible
(in contrast with peripheral blood neutrophils). The right column
shows the same cells photographed with a UV filter to highlight the
Hoechst-stained nuclei.
FIG. 4. Ikaros RNA splicing variants in myeloid lineage cells. Four
populations representing different classes of myeloid lineage cells were
purified based on differential levels of Mac-1 and Gr-1 staining.
Populations A and C represent bone marrow and peripheral blood
neutrophils, respectively. Populations B and D would represent more
heterogeneous groups of immature myeloid cells and monocytes,
respectively. RT-PCR conditions were identical to those described in
Fig. 2.
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inefficient. We did not detect the novel isoforms Ik-2A and
Ik-4A in the myeloid lineages.
Ikaros Is Principally Localized to Heterochromatin in
Pre-B Cell Lines. Given the punctate staining pattern of Ikaros
in the nucleus of lymphoid cells, we examined the nuclear
localization pattern more closely by using immunogold elec-
tron microscopy. We analyzed two Abelson-transformed pre-B
cell lines because of the pronounced punctate staining in these
cells. We were unable to obtain enough purified LT-HSC for
electron microscopy.
Unexpectedly, we found Ikaros localized predominantly to
the electron-dense or heterochromatic regions of the nucleus
(Fig. 5 and Table 2). Gold particles were specifically detected
in the nucleus and were distributed throughout the hetero-
chromatic regions. By using ultrathin sections (approximately
70 nm, which would represent about 1% of the thickness of the
nucleus), the frequency of positively stained sections relative
to the total number of sections examined was about 50%. This
observation is consistent with results using confocal micros-
copy, which showed that pre-B cells contain a limited number
(8–20) of Ikaros-stained, punctate foci within the nucleus (22).
One would therefore not expect to find Ikaros in all planes of
the nucleus even though immunofluorescence studies show
that all cells stain positively for Ikaros expression in pre-B cell
lines (unpublished observation). Within the positively stained
sections, an average of one to two particles were observed.
Staining with preimmune sera showed five randomly distrib-
uted gold particles in a survey of 65 sections. Statistics on gold
particle localization were compiled based on examination of
the first 50–60 stained sections. Localization was determined
by two independent persons based on examination of unla-
beled photographs to eliminate bias in assigning location of the
gold particles. The ratio of particles found in heterochromatin
versus euchromatin was 2.8 or 2.3 when using Ikaros antibodies
directed against N-terminal and C-terminal epitopes, respec-
tively (Table 2). The identical staining pattern was seen by
using either Ikaros antibody. The biased localization of
Ikaros to heterochromatin was particularly significant in that
a large percentage of the nuclear area consisted of euchro-
matin (Fig. 5A). Ikaros staining in heterochromatin associ-
ated with the nuclear envelope was approximately 2-fold
higher than in other heterochromatic regions within the
nucleus. However, this may have more to do with the total
surface area of the various regions than any distinct local-
ization pattern. Depending on the plane of sectioning
through the nucleus, it is possible that heterochromatin,
which in two dimensions appears to be centrally localized,
may actually be associated with the nuclear envelope. Ap-
proximately 5% of the gold particles were found within the
nucleolus. Cytoplasmic staining and localization to the pe-
rinuclear space was seen in rare instances.
FIG. 5. Ikaros localization in heterochromatin of pre-B lympho-
cytes. (A) One representative nucleus from the Abelson-transformed
pre-B cell line, bcl2–3, is shown at a magnification of 15,0003. The
euchromatic (a), heterochromatic (b), and nucleolar (c) regions are
indicated along with the nuclear envelope (d) and a nuclear pore (e).
(B, C) Low (15,0003) and high power (31,0003) images of a nucleus
stained with the anti-N-terminal Ikaros antibody. Localization of one
10-nm gold particle to heterochromatin associated with the nuclear
envelope is shown ( f).
Table 1. Summary of Ikaros RNA expression in
hematopoietic subsets
IK-1 IK-2
IK-2Ay
IK-4* IK-4A IK-6
LT-HSC X X
ST-HSC X X X X
MPP X X 2A X
Lymphoid progenitor X X X X X
pro-B X X X(4) X X
pro-T X X X X X
Neutrophil† X X 4 X
*For the IK-2AyIK-4 comigrating bands. “X” represents the presence
of a band, and 2A or 4 indicates a positive identification by sequence.
The IK-4 identified as pro-B was sequenced in an Abelson-
transformed pre-B cell line and has been identified in a T cell line by
Molnar and Georgopoulos (16). All other X designations come from
RT-PCR analyses of normal cells sorted by FACS according to their
distinctive phenotype.
†Neutrophils generally contained only one of the indicated isoforms in
five-cell PCRs.
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To confirm the specificity of heterochromatin staining, we
used a control anti-Elf-1 antibody (23). Elf-1 is a member of
the ETS family of transcriptional activating proteins and is
believed to positively activate transcription of genes like TdT
in immature lymphocytes (23). In contrast with Ikaros, Elf-1
was predominantly localized to the lighter, euchromatic re-
gions of the nucleus (Table 2). The ratio of gold particles in
heterochromatin versus euchromatin was reciprocally related
to that observed in Ikaros-stained samples, with Elf-1 being
found 2-fold more frequently in euchromatin than in hetero-
chromatin. Staining was again specific for the nucleus and
could be found in approximately 50% of the total number of
nuclei examined. Only 3% of the particles were found within
the nucleolus.
DISCUSSION
One hypothesis to explain the lack of lymphoid cells in
Ikaros-deficient animals is that Ikaros may function as a
master regulator of lymphoid commitment from multipotent
progenitor cells. A simple prediction would be that Ikaros is
transcriptionally activated in cells that are undergoing the
transition from a multipotent cell to a lymphoid-restricted
progenitor. Our results show that the DNA-binding isoforms
of Ikaros (principally Ik-2 but also Ik-1) are nuclearly localized
in all LT-HSC (Figs. 1 and 2). These isoforms of Ikaros are
therefore not sufficient to induce lymphoid commitment from
multipotential cells unless their activity is being post-
transcriptionally regulated. A recently published paper (18)
also concluded that Ikaros is present in stem cells, although the
cell surface phenotype of the sorted cells would suggest that
the population analyzed contained mainly non-HSC (3, 24).
As multipotent cells differentiated into lymphoid-
committed progenitors, the smallest Ikaros isoform, Ik-6, was
seen in one out of eight PCR reactions using five cells. The
other isoforms in lymphoid-committed progenitors (Ik-1 in
5y8 reactions, Ik-2 in 5y8 reactions, and Ik-2AyIk-4 in 2y8
reactions) are similar to those seen in the ST-HSC and
non-self-renewing MPP populations. Committed pro-B and
pro-T cell populations both expressed Ik-6 in a fraction of the
samples along with Ik-4 and at least one of the other induced
isoforms (Ik-4A, Fig. 2 and Table 1). Isoform 6 was the only
splice variant that was associated with lymphoid commitment,
albeit in only a fraction of the samples that were analyzed. Ik-6
was also found in a number of myeloid cell populations (Fig.
4), so its expression correlates more with differentiation of
multipotential cells into both myeloid and lymphoid-
committed progenitors. The expression of Ik-4 may be corre-
lated with lymphoid commitment, although its comigration
with Ik-2A made this difficult to evaluate. At all stages in the
differentiation process, high levels of Ik-2 were expressed in
almost every sample.
What then might be the role of alternative splicing in the
differentiation of LT-HSC into ST-HSC and in the transition
between multipotent progenitor and lymphoid-committed
progenitor? Purification of Ikaros from lymphocyte extracts
using DNA affinity chromatography demonstrates that Ik-6 is
tightly associated with other Ikaros isoforms and at least two
additional zinc-finger proteins, one of which is the recently
described Aiolos protein (18), in a multi-subunit complex that
can bind DNA (K. Hahm and S. Smale, unpublished results).
In contrast, gel shift experiments and transient cotransfection
studies suggest that Ik-6 inhibits the DNA-binding and func-
tional activity of the larger Ikaros isoforms (17). Both of these
observations suggest that induced isoforms, like Ik-2A, Ik-4A,
Ik-4, and Ik-6, have the potential of altering the composition
of the complex and perhaps the specificity of the complex for
certain DNA binding sites. The induced isoforms may also
function to modulate the ability of Ikaros to interact with other
proteins found in the Ikaros complex, which themselves may be
the key regulators of lymphocyte development.
To understand how Ikaros might influence neutrophil de-
velopment, we examined Ikaros expression in neutrophils and
myeloid progenitors. We found that neutrophils and other
myeloid cell populations expressed Ikaros isoforms that were
similar to those found in lymphocytes, with the exception that
Ik-6 was more frequently seen in myeloid cells (Figs. 3 and 4).
Neutrophils also did not express the multipotent progenitor
isoforms Ik-2A and Ik-4A. Curiously, only 50% of the samples
had what was usually a single amplified band (Fig. 4). A similar
amplification pattern was seen in stem cell and lymphocyte
reactions when one cell was analyzed, which supports the
notion that limited amounts of Ikaros mRNA may lead to
biased PCR reactions and the preferential amplification of
single bands (unpublished observation). We cannot rule out
the possibility that only one of the various splice junctions is
utilized at any given time within a single cell. At another time
in the life history of that same cell, another splice form might
predominate. The expression of Ikaros in neutrophils suggests
that the lack of Gr-11 cells in the mutant mice is probably a
deficit in the regulation of genes necessary for differentiation
of neutrophils from myeloid progenitor cells. In Ikaros knock-
out mice, these progenitors retain the capacity to differentiate
along erythroid and monocytic pathways (11, 12).
The punctate nuclear staining pattern of Ikaros in HSC and
lymphocytes (Fig. 1) resembles that seen in the putative
mammalian homolog of the Drosophila polycomb complex (25,
26). The polycomb proteins (reviewed in refs. 27–29) function
by maintaining the repressed state of different clusters of
homeotic genes. Mice with a targeted disruption of the bmi-1
proto-oncogene show severe skeletal and hematopoietic ab-
normalities (25), which may be a consequence of derepressed
homeotic genes. Although Ikaros null animals are viable (12),
they do display a severe hematopoietic phenotype that may be
a consequence of derepressed genes regulating developmental
decisions in hematopoietic stem cells.
In support of the notion that Ikaros might function as a
negative regulator of transcription, we found a surprising
localization of Ikaros predominantly to heterochromatin in
Abelson-transformed pre-B cell lines by using immunogold
electron microscopy (Fig. 5 and Table 2). Brown et al. (22)
recently made similar observations by using confocal micros-
copy. It is possible that the largely heterochromatic localization
of Ikaros proteins in Abelson-transformed pre-B cells is only
representative of leukemic cells and not the variety of normal
hematolymphoid stages studied here. However, the contrast-
ing localization of Elf-1 predominantly to euchromatin and
Ikaros to heterochromatin in the same cell line suggests that
these localizations are specific and not simply the reflection of
relative DNA content in heterochromatin versus euchromatin
(Table 2).
A number of possible models should be considered. Ikaros
may act as a classical repressor and bind important regulatory
cis-acting sequences in specific promoter or enhancer regions.
This may block access of basal transcription machinery to the
promoter or block binding of key activators to their sites in
lymphoid or myeloid genes. If this occurs in euchromatin, it
Table 2. Nuclear localization patterns of Ikaros and Elf-1 in
pre-B cells
Antibody
# nuclei
analyzed
Hetero-
chromatin* Euchromatin
Het:Eu
ratio
Ikaros (N-terminal) 52 55 20 2.75
Ikaros (C-terminal) 61 72 32 2.25
Elf-1 55 35 60 0.58
*The proportion of gold particles localized to heterochromatin did not
differ significantly between the two Ikaros antibodies. There was a
highly significant difference (P , 0.001) between either Ikaros
antibody and Elf-1 by pairwise z-tests.
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could play a role in inducing heterochromatin formation (see
below). Interestingly, a recent paper has shown that Ikaros and
Ets family members compete for binding to an important
cis-regulatory element within the TdT promoter (23). From
that study, it seems that Ets family members, in particular
Elf-1, may positively regulate TdT transcription in vivo. Con-
sistent with this, the chromatin localization of Elf-1 in pre-B
cells is largely restricted to euchromatic regions (Table 2).
Ikaros may also inhibit expression of target genes by associ-
ating with proteins that regulate the condensed state of
chromatin. For example, Ikaros could facilitate the formation
of heterochromatin around different sets of genes, and these
events could require particular isoforms of Ikaros. In that view,
different Ikaros isoforms could act as targets for proteins that
aid in the formation andyor maintenance of heterochromatin
like those of the mammalian polycomb group. Ikaros could
also function by targeting multiprotein complexes involved in
the heterochromatin to euchromatin switch, like SWIySNF
(30), to particular genes for activation. Finally, Ikaros may be
localized to heterochromatin without being necessary for
protein targeting, the maintenance of chromatin structure, or
for gene repression. That is to say, Ikaros may be localized to
heterochromatin as a structural protein or have a role other
than those possibilities enumerated above.
The observation that Ikaros can function as a transcriptional
activator when transiently cotransfected into a fibroblast cell
line along with a reporter gene containing multiple copies of
an Ikaros binding site seems inconsistent with our findings of
heterochromatin localization (16, 17). Many possible explana-
tions might address both observations. Ikaros function may be
dependent on the context of its binding site, with some genes
being actively repressed while other genes with different Ikaros
binding site configurations (which might bind different Ikaros
isoform assemblies) are actively transcribed. This would be
consistent with our observation that some gold particles in
Ikaros-stained nuclei localize to euchromatin as well as het-
erochromatin in pre-B cells (Table 2). Another possibility is
that Ikaros may only function as a repressor when genes are
stably integrated in chromatin, which would not be addressed
by the transient transfection approach.
From our data, a simple working model for the role of Ikaros
in stem cells might be to sequester genes in transcriptionally
inactive chromatin. Gene- and developmental stage-specific
activation of transcription would then occur, as specific acti-
vators of a given gene like Elf-1, Aiolos (18), p70 (K. Hahm and
S. Smale, unpublished work), and EBF (31, 32) would displace
Ikaros through direct binding to the cis sequence of a repressed
gene (23) or by direct association with the Ikaros complex
(Aiolos and p70). Other regulators of chromatin structure, like
SWIySNF proteins, may also be involved in the activation
process. Expression of the induced Ikaros isoforms (Ik-2A,
Ik-4, Ik-4A, and Ik-6) could also change the function of the
Ikaros complex during lymphoid development. In any case, the
observations that Ikaros is expressed in HSC, that different
isoforms are expressed in different hematopoietic progenitors,
and that Ikaros is localized to heterochromatin both further
complicate and inform models of Ikaros function. Future
studies may reveal the significance of these observations.
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